Clinical trial
FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG)…
NCT00309088 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00309088 |
|---|---|
| Title | FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients |
| Official title | FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myasthenia Gravis |
| Intervention type | Drug |
| Interventions | tacrolimus, placebo |
| Enrollment | 80 |
| Start date | Apr 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jun 1, 2008 |
| First posted | Mar 31, 2006 |
| Last update posted | Aug 25, 2014 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: